Doctoral dissertations

Doctoral dissertations supervised/co-supervised by/carried out in collaboration with the researchers at the Department of Clinical Pharmacology, University of Helsinki.

2018

  • Mikko Holmberg 

2017

  • Katriina Tarkiainen 

2016

  • Juho Heinonen 

2015

  • Päivi Ruokoniemi 

2014

  • Anne Filppula 

2012

  • Tuija Tapaninen 
  • Tiina Karonen 
  • Erik Litonius

2011

  • Johanna Honkalammi 
  • Xiaoqiang Xiang 

2009

  • Marjo Volotinen 
  • Samuel Fanta 
  • Mika Isohanni 

2008 

  • Annikka Kalliokoski 
  • Marjo Karjalainen 
  • Henna Rautiainen 
  • Kati Ahonen 
  • Kim Lemberg 
  • Marja Pasanen 
  • Aleksi Tornio 

2007

  • Tiina Jakkola 

2006 

  • Lauri Kajosaari 
  • Mia Koskinen 
  • Pentti Pöder 

2005

  • Marika Granfors 
  • Heli Malm 
  • Heikki Valleala 

2004

  • Carl Kyrklund 

2003

  • Hanna Kotikoski 
  • Kristiina Perttunen 
  • Mika Jokinen 
  • Matti Kivikko 
  • Kari Raaska 

2002

  • Xia Wen 

2001

  • Outi Lapatto-Reiniluoto 
  • Elina Saarenmaa 
  • Jun-Sheng Wang 
  • Jari Lilja 
  • Mikko Niemi 

2000

  • Tiina Varis 

1999

  • Teemu Kantola, Effects of itraconazole and some other CYP3A4 inhibitors on the pharmacokinetics of HMG-CoA reductase inhibitors.
  • Vilja Palkama, Studies on drug interactions between CYP3A4 inhibitors and anaesthetic drugs.
  • Kirsti Villikka, Studies on drug interactions caused by rifampicin and dexamethasone in humans.

1998 

  • Tommi Lamberg, Effects of inhibition and induction of CYP3A4 on the pharmacokinetics and pharmacodynamics of buspirone.

1997

  • Mirja Hämäläinen, L: Optimal drug treatment of recurrent headaches and migraine in children – a clinical and pharmacological study.
  • Kirsi-Maija Kaukonen, Studies on the effects of a CYP3A4-inhibitor, itraconazole, on the pharmacokinetics and pharmacodynamcis of cardiovascular drugs.
  • Seppo Kähkönen, Pharmacodynamic and pharmacokinetic aspects of propranolol, verapamil and isosorbide dinitrate during alcohol withdrawal.
  • Eeva Lukkari, Clinical pharmacology of oxybutynin, with special reference to pharmacokinetics and interaction.

1996

  • Reijo Laaksonen, The effect of HMG-CoA reductase inhibitor treatment on serum and skeletal muscle ubiquinone.
  • Jouni Ahonen, Studies on CYP3A mediated drug interactions in anaesthesiology.
  • Ari Illi, Inhibition of catechol-O-methyltransferase by entacapone: Effects on haemodynamics and catecholamine metabolism and interactions with drugs interfering with catecholamine disposition.
  • Harri Luurila, Effect of erythromycin on the pharmacokinetics and pharmacodynamics of hypnotics.
  • Anu Varhe, Interactions of triazolam with inhibitors of CYP3A enzymes.

1995

  • Janne Backman, Effects of drugs inhabiting and inducing CYP3A enzymes on the pharmacokinetics and pharmacodynamics of oral midazolam.

1994

  • Tapio Kuitunen

1993

  • Anne Lamminpää

1990

  • Riitta Tokola, Studies on drug absorption and efficacy in migraine attacks.

1989

  • Olavi Tokola

1987

  • Kalle Hoppu, Paediatric clinical pharmacology of trimethoprim.

1987

  • Eero Tiula, Effect of renal diseases on serum protein binding of drugs.

1985

  • Klaus Olkkola, Factors affecting the antidotal efficacy of oral activated charcoal.

1982

  • Jaakko-Juhani Himberg, Optimization and validation of gas-chromatographic drug assays for pharmacokinetic studies.

1981

  • Mirja-Liisa Aitio

1980

  • Sirkka Elfving, Studies on the naturally occurring goitrogen 5-vinyl-2-thiooxazolidone – metabolism and antithyroid effect in the rat.